Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages 323-329

  German, Polina ^a   Warren, David ^a   West, Steve ^a   Hui, James ^a   Kearney, Brian P ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

elvitegravir; fixed dose combination; integrase inhibitor; pharmacoenhancer; pharmacokinetics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; GS 9350; INTEGRASE; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ADENINE; DEOXYCYTIDINE; DRUG COMBINATION; INTEGRASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; QUINOLONE DERIVATIVE; TABLET;

ACUTE HEPATITIS; ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOAVAILABILITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG COMBINATION; HIV INFECTIONS; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMA; TABLET;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; PHOSPHONIC ACIDS; PLASMA; QUINOLONES; TABLETS; ORGANOPHOSPHONATES;

EID: 78049293198     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181eb376b     Document Type: Article

References (31)

1. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006;49:1506-1508.
2. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5.
3. Kearney BP, Mathias A, Zhong L, et al. Pharmacokinetics/pharmacody-namics of GS-9137 an HIV integrase inhibitor. Oral presentation. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed July 19, 2010.
5. Arribas JR, Iribarren JA, Knobel H, et al. Adherence, treatment satisfaction and effectiveness of once-daily (QD) vs twice-daily (BID) antiretroviral therapy (AT), in a large prospective observational cohort (CUVA Study). Poster WePeB5780. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
6. Maggiolo F, Migliorino M, Maserati R, et al. Once-a-day treatment for HIV infection: final 48-week results. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL.
7. Felizarta F, Becker S, Bellos N, et al. Adherence and efficacy with a once-daily efavirenz-based regimen: 48-week results from the Daily Antiretroviral Therapy II (DART II) Study. Poster 5842. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
8. Center RC. Division of AIDS (DAIDS) Table of Grading Severity of Adult and Pediatric Adverse Events. 2004. http://www.niaid.nih.gov/ LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegra-dingtable.pdf. Accessed April 29, 2010.
9. Droste JA, Kearney BP, Hekster YA, et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:37-43.
10. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43: 595-612.
11. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009; 29:924-929.
12. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007;45:274-279.
13. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.
14. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res. 1999;16:1206-1212.
15. Ray AS, Wright MR, Rhodes GR. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. Clin Pharmacol Ther. 2008;84:660; Author reply 661.
16. van der Sandt IC, Vos CMP, Nabulsi L, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 2001;15:483-491.
17. Cihlar T, Ray A, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267-272.
18. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:203-209.
19. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51: 3498-3504.
20. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278-283.
21. Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. Poster. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 26-29, 2005; Quebec, Canada.
22. Ray AS, Wright MR, Rhodes GR. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. Clin Pharmacol Ther. 2008;84:660.
23. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrobial Agents Chemother. 2007;51: 3498-3504.
24. Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Poster A-1617. Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
25. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9:213-224.
26. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53: 323-332.
27. Reyataz® (atazanavir sulfate) Capsules. US Prescribing Information [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. Revised January 2010.
28. KALETRA® (lopinavir/ritonavir) tablets (lopinavir/ritonavir) oral solution US Prescribing Information [package insert]. North Chicago, IL: Abbott Laboratories. Revised April 2009.
29. Emtriva® (emtricitabine) Capsules. US Prescribing Information [package insert]. Foster City, CA: Gilead Sciences, Inc. September 2004.
30. Modrzejewski KA, Herman RA. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother. 2004;38: 1006-1014.
31. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. J Am Med Assoc. 2004;292:180-190.